BS Identity and Score for TAGRISSO (AstraZeneca)

Parameter drift, trailing slash inconsistencies, and language leaks create unintended alternate identities. Get a Clinical Canonical Diagnosis to reveal where duplicate embeddings are silently created.

Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.

The site displays a review_count of 1 on some pages without any actual review content or verifiable third-party source, creating a minor trust theatre flag. However, it avoids standard marketing BS by providing a proof_links_count of up to 15 on registration pages, mostly linking to privacy notices and regulatory disclosures. The most significant theatre is the use of ‘Patient Stories’ headers that currently lead to ‘quote to come’ placeholders, promising emotional proof that does not exist in the current crawl.

Proof density is split: the regulatory and clinical proof is high (1 in 5 patients statistics, specific mutation types), but the social proof is non-existent. For every specific clinical assertion, there is a corresponding ‘fluff’ placeholder such as ‘Name X’ or ‘Inspirational quote.’ Across 4 pages, we find 2 solid clinical study citations against 3 major template placeholders, resulting in a mediocre proof-to-assertion ratio for a biotech entity.

To review a full competitive diagnostic applied to an enterprise level technical SEO agency, including a direct comparison against Dejan, examine the complete executive audit. View the iPullRank Executive SEO Strategy Dashboard for a practical example of how perception gaps, value prop drift, and audience misalignment are surfaced in real audits.

Authority is primarily established through the AstraZeneca brand, but the site’s technical implementation lacks modern authority signals like schema_json, which is null across the board. While Dr. Sarada Gurubhagavatula is mentioned as an expert, there is no Person schema or sameAs links to verify her credentials or professional footprint. The technical credibility gap is widened by the broken heading hierarchy where H1 tags are used for non-semantic brand slogans rather than medical information.

The performance claims regarding TAGRISSO’s efficacy (e.g., ‘help prevent your lung cancer from coming back’) are generally backed by citations to clinical references like Sholl et al (2015). However, there is a disconnect in the ‘Patient Experience’ claims, which are framed as ‘Stories’ (Deb, Elise, Lloyd) but frequently lack the actual narrative substance or dated metrics in the body text. The site claims a supportive community but provides only a link to a general Facebook group, lacking integrated real-world evidence.

The site content perfectly aligns with the Pharma & Biotech category, specifically focusing on oncology and targeted therapies for EGFR+ NSCLC. It utilizes heavy regulatory-required documentation such as Important Safety Information (ISI) and cites peer-reviewed studies (Sholl et al., D’Angelo et al.), confirming its status as a pharmaceutical product site.

If your structural signals drift, the model cannot form stable chunks or coherent embeddings. Study the Semantic HTML Framework Guide and see why semantic structure — not styling — controls AI comprehension.

“The score of 45 is driven primarily by the 'Identity and Authority' and 'Information Density' pillars due to the catastrophic presence of placeholder text and nonsensical H1 headers. While the clinical data is highly substantive (lowering the potential score), the technical execution is so indicative of a generic template failure that it introduces significant 'Bullshit' via neglect. The lack of structured data and the presence of dummy names like 'Name X' are the primary credibility killers.”